l General Information |
Product Name | Riluzole |
General description | Riluzole, a member of the benzothiazole class, is indicated for the treatment of patients with amyotrophic lateral sclerosis (ALS). |
Synonym | 6-(trifluoromethoxy)-1,3-benzothiazol-2-amine; RP-54274; PK 26124 |
Purity | ≥98%(HPLC) | CAS Number | 1744-22-5 |
Formula | C8H5F3N2OS | Molecular Weight | 234.2 |
Suitability | BioReagent, suitable for cell culture, etc. |
l Physical and Chemical Information |
Appearance | almost white solid |
Solubility(25°C) | DMSO | ≥40mg/mL |
Ethanol | ≥40mg/mL |
Water | Insoluble |
l Biological Information |
Biochem/Physiol
Actions | Riluzole, a member of the benzothiazole class, is indicated for the treatment of patients with amyotrophic lateral sclerosis (ALS). Riluzole extends survival and/or time to tracheostomy. It is also neuroprotective in various in vivo experimental models of neuronal injury involving excitotoxic mechanisms. The etiology and pathogenesis of amyotrophic lateral sclerosis (ALS) are not known, although a number of hypotheses have been advanced. One hypothesis is that motor neurons, made vulnerable through either genetic predisposition or environmental factors, are injured by glutamate. In some cases of familial ALS the enzyme superoxide dismutase has been found to be defective. |
l Storage |
Storage temp. | -20℃ |
l Precautions and Disclaimer |
This product is for R&D use only, not
for drug, household, or other uses. |
l References |
1. http://www.drugbank.ca 2. https://ncit.nci.nih.gov 3. https://www.ncbi.nlm.nih.gov |
